25
Participants
Start Date
December 10, 2020
Primary Completion Date
August 24, 2021
Study Completion Date
August 24, 2021
ABBV-47D11
Intravenous (IV) infusion.
Placebo for ABBV-47D11
Intravenous (IV) infusion.
ABBV-2B04
Intervenous (IV) Infusion
Placebo for ABBV-2B04
Intervenous (IV) Infusion
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 226015, Budapest
Semmelweis Egyetem /ID# 226016, Budapest
University of Miami /ID# 225038, Miami
The Christ Hospital /ID# 224541, Cincinnati
Sheba Medical Center /ID# 225857, Tel Hashomer, Ramat Gan
Hadassah Medical Center-Hebrew University /ID# 225827, Jerusalem
Glendale Adventist Medical Center /ID# 225188, Glendale
Beautiful Minds Clinical Research Center /ID# 228708, Cutler Bay
Triple O Research Institute /ID# 228612, West Palm Beach
University of Illinois Hospital and Health Sciences System /ID# 224323, Chicago
Pikeville Medical Center /ID# 224539, Pikeville
Saint Peter's University Hospital /ID# 225183, New Brunswick
Saint Michael's Medical Center /ID# 225258, Newark
Prisma Health Children's Hospital Upstate /ID# 224556, Greenville
Gadolin Research, LLC /ID# 229394, Beaumont
Universitair Medisch Centrum Utrecht /ID# 225919, Utrecht
San Juan Bautista School of Medicine /ID# 225963, Caguas
Manati Medical Center /ID# 225936, Manatí
Lead Sponsor
AbbVie
INDUSTRY